Literature DB >> 9743306

A multivariate analysis of tumour biological factors predicting response to cytotoxic treatment in advanced breast cancer.

J Sjöström1, S Krajewski, K Franssila, E Niskanen, V M Wasenius, S Nordling, J C Reed, C Blomqvist.   

Abstract

The study was designed to identify factors that could predict response to chemotherapy in breast cancer. A total of 173 patients with measurable or evaluable metastatic breast cancer were enrolled in a randomized trial between November 1987 and January 1991 to receive a monthly dose of 5-fluorouracil (500 mg m(-2)), epirubicin (60 mg m(-2)) and cyclophosphamide (500 mg m(-2)) either administered in four weekly doses or in an every-4-week dose as first-line cytotoxic treatment. In 103 evaluable patients we performed a multivariate analysis of the tumour biological factors, i.e. histological grade, oestrogen receptor (ER), progesterone receptor (PR), S-phase fraction (SPF), ploidy, p53, c-erbB-2, Bcl-2 and Bax expression, which showed significance in the univariate analysis according to treatment response, time to progression (TTP) or overall survival (OS). In the univariate analysis only SPF, grade and the proapoptotic protein Bax correlated with the response to cytotoxic treatment. In the multivariate analysis SPF had the strongest correlation, followed by grade and Bax. In the univariate analysis grade, PR, Bax and Bcl-2 correlated significantly with TTP, whereas in the multivariate analysis only PR showed a statistically significant correlation. In the univariate analysis PR and Bax correlated with OS and both retained its significance in the multivariate analysis. The factors that correlated significantly with the response to cytotoxic treatment in the univariate analysis, i.e. grade, SPF and Bax, seemed to predict independently the response to treatment in the multivariate analysis also. TTP and OS could be predicted partly by the same factors, although the association was quite weak. More studies and new tumour biological factors are needed to identify the group of breast cancer patients who get the most benefit from chemotherapy.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9743306      PMCID: PMC2062970          DOI: 10.1038/bjc.1998.584

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  11 in total

Review 1.  Predictive factors for response to cytotoxic treatment in advanced breast cancer: a review.

Authors:  J Sjöström; C Blomqvist
Journal:  Acta Oncol       Date:  1996       Impact factor: 4.089

2.  Immunohistochemical analysis of Mcl-1 and Bcl-2 proteins in normal and neoplastic lymph nodes.

Authors:  S Krajewski; S Bodrug; R Gascoyne; K Berean; M Krajewska; J C Reed
Journal:  Am J Pathol       Date:  1994-09       Impact factor: 4.307

3.  Immunohistochemical determination of in vivo distribution of Bax, a dominant inhibitor of Bcl-2.

Authors:  S Krajewski; M Krajewska; A Shabaik; T Miyashita; H G Wang; J C Reed
Journal:  Am J Pathol       Date:  1994-12       Impact factor: 4.307

4.  Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up.

Authors:  C W Elston; I O Ellis
Journal:  Histopathology       Date:  1991-11       Impact factor: 5.087

5.  Correlation of pretreatment proliferative activity of breast cancer with the response to cytotoxic chemotherapy.

Authors:  Y Remvikos; P Beuzeboc; A Zajdela; N Voillemot; H Magdelénat; P Pouillart
Journal:  J Natl Cancer Inst       Date:  1989-09-20       Impact factor: 13.506

6.  Influence of treatment schedule on toxicity and efficacy of cyclophosphamide, epirubicin, and fluorouracil in metastatic breast cancer: a randomized trial comparing weekly and every-4-week administration.

Authors:  C Blomqvist; I Elomaa; P Rissanen; P Hietanen; K Nevasaari; L Helle
Journal:  J Clin Oncol       Date:  1993-03       Impact factor: 44.544

7.  Reduced expression of proapoptotic gene BAX is associated with poor response rates to combination chemotherapy and shorter survival in women with metastatic breast adenocarcinoma.

Authors:  S Krajewski; C Blomqvist; K Franssila; M Krajewska; V M Wasenius; E Niskanen; S Nordling; J C Reed
Journal:  Cancer Res       Date:  1995-10-01       Impact factor: 12.701

8.  Immunohistochemical analysis of P-glycoprotein expression correlated with chemotherapy resistance in locally advanced breast cancer.

Authors:  J Ro; A Sahin; J Y Ro; H Fritsche; G Hortobagyi; M Blick
Journal:  Hum Pathol       Date:  1990-08       Impact factor: 3.466

9.  Predictive value of c-erbB-2, p53, cathepsin-D and histology of the primary tumour in metastatic breast cancer.

Authors:  E Niskanen; C Blomqvist; K Franssila; P Hietanen; V M Wasenius
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

10.  Do DNA ploidy and S-phase fraction in primary tumour predict the response to chemotherapy in metastatic breast cancer?

Authors:  P Hietanen; C Blomqvist; V M Wasenius; E Niskanen; K Franssila; S Nordling
Journal:  Br J Cancer       Date:  1995-05       Impact factor: 7.640

View more
  10 in total

1.  Amplification and deletion of topoisomerase IIalpha associate with ErbB-2 amplification and affect sensitivity to topoisomerase II inhibitor doxorubicin in breast cancer.

Authors:  T A Järvinen; M Tanner; V Rantanen; M Bärlund; A Borg; S Grénman; J Isola
Journal:  Am J Pathol       Date:  2000-03       Impact factor: 4.307

2.  Clinical and pathological predictors of the response to neoadjuvant anthracycline chemotherapy in locally advanced breast cancer.

Authors:  Mónica Fernández-Sánchez; Armando Gamboa-Dominguez; Norma Uribe; Ana Cristina García-Ulloa; Diana Flores-Estrada; Myrna Candelaria; Oscar Arrieta
Journal:  Med Oncol       Date:  2006       Impact factor: 3.064

Review 3.  The essential role of evasion from cell death in cancer.

Authors:  Gemma L Kelly; Andreas Strasser
Journal:  Adv Cancer Res       Date:  2011       Impact factor: 6.242

4.  Estrogen receptor expression and docetaxel efficacy in patients with metastatic breast cancer: a pooled analysis of four randomized trials.

Authors:  Fabrice Andre; Kristine Broglio; Lajos Pusztai; Narjiss Berrada; John R Mackey; Jean Marc Nabholtz; Stephen Chan; Gabriel N Hortobagyi
Journal:  Oncologist       Date:  2010-04-26

5.  Her-2/neu expression as a predictive factor for response to anthracycline-based chemotherapy in a mexican population of locally advanced breast cancer patients.

Authors:  David Muñoz-Gonzalez; Isabel Zeichner-Gancz; Myrna Candelaria; Maria Teresa Ramirez-Ugalde; Manuel Perez-Sanchez; Guadalupe Cervantes-Vazquez; David Cantu-de Leon; Arcelia Mora-Tizcareño; Julio Leonor-Ortíz
Journal:  Med Oncol       Date:  2005       Impact factor: 3.064

Review 6.  Apoptosis and cancer: the genesis of a research field.

Authors:  Thomas G Cotter
Journal:  Nat Rev Cancer       Date:  2009-07       Impact factor: 60.716

7.  Number of apoptotic cells as a prognostic marker in invasive breast cancer.

Authors:  J S de Jong; P J van Diest; J P Baak
Journal:  Br J Cancer       Date:  2000-01       Impact factor: 7.640

8.  Improvement of the clinical applicability of the Genomic Grade Index through a qRT-PCR test performed on frozen and formalin-fixed paraffin-embedded tissues.

Authors:  Jérôme Toussaint; Anieta M Sieuwerts; Benjamin Haibe-Kains; Christine Desmedt; Ghizlane Rouas; Adrian L Harris; Denis Larsimont; Martine Piccart; John A Foekens; Virginie Durbecq; Christos Sotiriou
Journal:  BMC Genomics       Date:  2009-09-10       Impact factor: 3.969

Review 9.  Meta-analysis confirms BCL2 is an independent prognostic marker in breast cancer.

Authors:  Grace M Callagy; Mark J Webber; Paul D P Pharoah; Carlos Caldas
Journal:  BMC Cancer       Date:  2008-05-29       Impact factor: 4.430

10.  Bax regulates c-Myc-induced mammary tumour apoptosis but not proliferation in MMTV-c-myc transgenic mice.

Authors:  M H Jamerson; M D Johnson; S J Korsmeyer; P A Furth; R B Dickson
Journal:  Br J Cancer       Date:  2004-10-04       Impact factor: 7.640

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.